AstraZeneca: successful Phase III trial for Tezspire
(CercleFinance.com) - AstraZeneca and Amgen announce that a Phase III trial of Tezspire (tezepelumab) showed a statistically significant and clinically relevant reduction in nasal polyp size and nasal congestion in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), compared with placebo.
This randomised, double-blind trial evaluated the efficacy and safety of Tezspire in adults presenting symptoms despite standard treatment (intranasal corticosteroids).
These data could offer patients a new option, reducing the need for cumbersome interventions.
The results will be communicated to regulatory authorities and at a forthcoming scientific meeting, says the laboratory.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
This randomised, double-blind trial evaluated the efficacy and safety of Tezspire in adults presenting symptoms despite standard treatment (intranasal corticosteroids).
These data could offer patients a new option, reducing the need for cumbersome interventions.
The results will be communicated to regulatory authorities and at a forthcoming scientific meeting, says the laboratory.
Copyright (c) 2024 CercleFinance.com. All rights reserved.